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Alternatively spliced variants of fibronectin (FN) containing exons EIIIA and EIIIB are expressed around newly forming vessels in development
and disease but are downregulated in mature vasculature. The sequences and patterns of expression of these splice variants are highly conserved
among vertebrates, suggestive of their biological importance; however the functions of EIIIA and EIIIB-containing FNs are unknown. To understand
the role(s) of these splice variants, we deleted both EIIIA and EIIIB exons from the FN gene and observed embryonic lethality with incomplete
penetrance by embryonic day 10.5. Deletion of both EIIIA and EIIIB exons did not affect synthesis or cell surface deposition of FN, indicating that
embryonic lethality was due specifically to the absence of EIIIA and EIIIB exons from FN. EIIIA/EIIIB double-null embryos displayed multiple
embryonic cardiovascular defects, including vascular hemorrhage, failure of remodeling embryonic and yolk sac vasculature, defective placental
angiogenesis and heart defects. In addition, we observed defects in coverage and association with dorsal aortae of alpha-smooth-muscle-actin-
positive cells. Our studies indicate that the presence or absence of EIIIA and EIIIB exons alters the function of FN and demonstrate the requirement
for these alternatively spliced exons in cardiovascular development.
© 2007 Elsevier Inc. All rights reserved.Keywords: Cardiovascular development; Fibronectin; Alternative splicingIntroduction
Organismal development, whether in invertebrates or verte-
brates, involves extensive migration of cells and germ layers to
generate the animal body plan. These migrations take place
through a variety of adhesive cell–cell and cell–matrix inter-
actions. Extracellular matrix provides both adhesive and sig-
naling platforms for the migrating cells, (reviewed in Hynes,
1990; Hynes, 2002; Lauffenburger and Horwitz, 1996; Schwartz
et al., 1995). While many extracellular matrix molecules such as
laminins and collagens appeared early in evolution and areAbbreviations: FN, fibronectin; EIIIA, EIIIB, extra fibronectin type III
domain A or B; αSMA, alpha smooth muscle actin; PECAM, platelet/
endothelial cell adhesion molecule; MEF, mouse embryo fibroblasts; ES cells,
embryonic stem cells; NEM, N-ethyl maleimide; PMSF, phenylmethylsulpho-
nyl fluoride; EDTA, ethylenediaminetetraacetic acid.
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doi:10.1016/j.ydbio.2007.07.005conserved from fly to human, fibronectin (FN) has been found
only in vertebrates and its appearance in evolution correlates
with the appearance of organisms with endothelial cell-lined
vasculature (Hynes and Zhao, 2000; Whittaker et al., 2006).
Consistent with this observation, FN is essential for early
embryonic development; mice lacking FN die by embryonic day
9.5 with severe cardiovascular defects, including malformed or
absent embryonic vessels and heart (George et al., 1993;
Georges-Labouesse et al., 1996).
FN is a complex, alternatively spliced multidomain protein.
FN domains are classified into type I (twelve domains), type II
(two domains) and type III (fifteen–seventeen domains) FN
repeats. In addition, FN is alternatively spliced at three regions
which can be included or excluded, either completely (EIIIA,
EIIIB, both type III repeats) or partially (the V region),
generating up to 12 different variants in rodents and 20 in
humans (Hynes, 1990; Kornblihtt et al., 1985; Kornblihtt et al.,
1984a; Pankov and Yamada, 2002; Schwarzbauer et al., 1987).
These splice variants are differentially expressed in development
and disease, both spatially and temporally (ffrench-Constant and
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Peters and Hynes, 1996; Tan et al., 2004). The importance of
some repeats is well known; for example, the 9th and 10th type
III repeats as well as the V region function in cell adhesion to
cell-surface integrins (Aota et al., 1991; Guan and Hynes, 1990;
Hynes, 1990; Pankov and Yamada, 2002), the 13th type III
repeat is important for binding to proteoglycans and for
assembly of actin stress fibers (Bloom et al., 1999; Wierz-
bicka-Patynowski and Schwarzbauer, 2003); the functions of
other repeats are not understood. While being distinct from each
other in sequence, all of the FN repeats are conserved through
evolution, suggesting importance of each of these repeats for the
functions of FN. The alternative splicing of FN introduces
another level of complexity and raises questions such as whether
the inclusion or exclusion of the alternatively spliced domains
alters the functions of FN and the biological consequences of
their presence or absence.
Alternative splicing of EIIIA and EIIIB exons of FN is
dynamically regulated in vivo. These splice variants are ex-
pressed at very low levels or not at all in the adult (Peters et al.,
1996). However, during embryogenesis, both EIIIA and EIIIB
exons become included into cellular FN (Peters and Hynes,
1996) and, in adults, these splice variants appear during
pathological processes requiring growth and/or remodeling of
the existing vasculature (Carnemolla et al., 1989; Glukhova
et al., 1989; Peters et al., 1988; Shekhonin et al., 1990; Trachsel
et al., 2007).
There is a strong correlation between the expression of EIIIA
and EIIIB and the presence of vascular remodeling. During
embryonic development, EIIIA and EIIIB are expressed around
embryonic vessels (ffrench-Constant and Hynes, 1989; Peters
andHynes, 1996); but this expression ceases when the process of
vascular development is complete (ffrench-Constant and Hynes,
1989; Peters et al., 1996). In adults, there is little or no detectable
expression of EIIIA and EIIIB around quiescent vasculature in
either mouse or human. However, during pathological angio-
genesis, for example in the process of tumor development, these
exons become included into FN. In fact, all human and murine
tumors that have been examined for the presence of these splice
variants show their abundant expression in the extracellular
matrix surrounding tumor vessels (references in (Astrof et al.,
2004; Castellani et al., 2002; Oyama et al., 1989). This
correlation is so striking that it has led to the development of
anti-EIIIB antibody as a tumor-targeting and a tumor-imaging
reagent in mice and humans (Borsi et al., 2002; Kaspar et al.,
2006; Nilsson et al., 2001).
Other pathological processes during which EIIIA and EIIIB
are included in the FN are wound healing, atherosclerosis, and
myocardial infarction, all of which require vascular remodeling
(ffrench-Constant et al., 1989; Matter et al., 2004; Shekhonin
et al., 1990). In spite of their high degree of sequence conser-
vation among vertebrate species and the evolutionarily con-
served regulation of their expression patterns, the functions of
these splice variants have remained a mystery for nearly two
decades since their original discovery.
A number of in vitro studies have claimed various, often
discordant (from no effect to some) effects of inclusion of EIIIAor EIIIB exons on cell attachment, migration, proliferation, cell
survival, matrix assembly, or expression of smooth muscle α
actin (Chen and Culp, 1996; Guan et al., 1990; Hashimoto-
Uoshima et al., 1997; Manabe et al., 1999; Serini et al., 1998;
Xia and Culp, 1994). However, in vivo, the individual deletion
of EIIIA or EIIIB has not given much insight into the possible
functions of these splice variants. EIIIA-null or EIIIB-null mice
are viable and fertile, and physiological angiogenesis such as
embryonic vascular development and retinal angiogenesis after
birth proceeded apparently normally in these mice (Astrof et al.,
2004; Fukuda et al., 2002; Muro et al., 2003; Tan et al., 2004).
Tumor growth and angiogenesis examined in the transgenic Rip-
Tag tumor model were not significantly affected by the absence
of either of the splice variants. Furthermore, contrary to
expectations, the development of αSMA-positive cells was not
affected (Astrof et al., 2004). However the absence of EIIIAwas
mildly protective in an atherosclerosis model (Tan et al., 2004).
In one study, a delay in cutaneous wound healing in EIIIA-null
mice was noted (Muro et al., 2003), but this effect was not
replicated in another study (Tan et al., 2004). Interestingly, a
possible effect of EIIIB on FNmatrix assembly and proliferation
was observed in EIIIB-null MEFs in vitro and recombinant
EIIIB-positive FN incorporated somewhat more efficiently into
ECM (Fukuda et al., 2002; Guan et al., 1990), suggesting a
possible role for EIIIB in FN matrix assembly.
Since the EIIIA and EIIIB splice variants are highly con-
served in sequence and expression pattern among species, we
reasoned that simultaneous deletion of both of these exons might
allow us to understand their function(s). Indeed, the absence of
both EIIIA and EIIIB was embryonic lethal in the majority of
embryos leading to severe cardiovascular defects. Here we
report the phenotypes of the EIIIA /EIIIB-double-null embryos
and the possible functions of EIIIA and EIIIB in vascular
development.
Materials and methods
Generation of EIIIA and EIIIB double-null mice
EIIIB-null ES cells were generated from EIIIB-null mice (Fukuda et al.,
2002) by isolating EIIIB-null zygotes. Zygotes were cultured in KSOMmedium
(Chemicon, Temecula, CA) for 3 days until blastocyst stage and then plated on a
monolayer of mouse embryo fibroblasts (MEFs) in ES cell medium containing
1000U/ml LIF (Chemicon) and 50 μMMEK inhibitor PD98059 (Cell Signalling
Technology, Danvers, MA) as described (Nagy et al., 2003). Following 4 days of
incubation, ES cell colonies were picked, trypsinized and plated on a monolayer
of MEFs. Two independent clones of EIIIB-null ES cells were isolated and tested
for germline transmission. One of the clones, B8, was selected for further
targeting to generate the EIIIA-null allele. The EIIIA-null allele was generated as
described (Tan et al., 2004) using a targeting construct generously provided by
Elizabeth George, and subsequent transfection of the targeted ES cells with Cre
recombinase-encoding plasmid, pMC-Cre (Gu et al., 1993). Southern blots were
performed using restriction enzymes EcoRI, HindIII, and BamHI and probe 2
(Tan et al., 2004) as well as restriction enzyme AvrII with probes 2 and sub44
(Fig. 2). Correctly targeted ES cell clones were injected into blastocysts derived
from FVB/NJ mice and chimeric mice were mated with C57BL6/J wild-type
mice. The progeny were genotyped using primers 5′-GTA CGTAAC CAATGC
TCGGT-3′ (primer 4) and 5′-CACAGACTATTCCATCCTAGAGATAG -3′
(primer 5) to detect EIIIA-null (1233 bp) and wild-type (2092 bp) alleles and 5′-
GCA CAC TTT GGA GGC CTG TCT TAG-3′ (primer 1), 5′-GAA AGC AAG
CCATGG GGG GCC TGG CC - 3′ (primer 2), 5′-CCT GGC CTG GAG TAC
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(616 bp; 2099 bp wild-type band was not detected under the PCR conditions
used) alleles. Genomic PCR primers described previously (Fukuda et al., 2002;
Tan et al., 2004) were also used to genotype EIIIA-null and EIIIB-null alleles.
The PCR results were confirmed by Southern blot using AvrII restriction enzyme
and probe 2 (see Fig. 2C).
Quantification of FN message and protein levels
RT-PCR
RNA from e9.5 embryos was isolated using Trizol (Invitrogen, Carlsbad,
CA) according to the manufacturer's instructions. RNAwas treated with RNase-
free DNase, repurified and used for reverse transcription. The presence or
absence of EIIIA or EIIIB exons in FN mRNAwas detected as described (Astrof
et al., 2004). To quantify FN mRNA levels, quantitative real-time PCR was
performed using primers 5′-CCT CTC TGG AAG AAG TGG TCC-3′ and 5′-
GACGTTGTACTCCAGGCCAG-3′ lying within the 7b (III7b) exon, primers
5′-CTC CCA CGG ATC TGC GAT TC-3′ and 5′-GGT TGG TCA GCT CGA
TGG AC-3′ lying within the III8a exon and primers 5′-GTT CAG TCA GGT
GACACCCAC-3′ and 5′-CCTGTC TTC TCT TTCGGGTTC-3′ lying within
the III12a exon. RNA levels of mouse GAPDH served as controls. Incorporation
of SYBR green into double-stranded PCR products was monitored using Biorad
iCycler.
Western blotting
Wild-type, heterozygous and null embryos were isolated at e9.5 or e14.5.
Trunks of e9.5 and heads of e14.5 embryos were lysed as described (Senger et al.,
1983). Briefly, frozen embryos were resuspended in 500 μl of SDS lysis buffer
using 27-gauge needle. The lysis buffer contained 0.1 M Tris–HCl pH 8.0, 0.2%
SDS, protease inhibitors (one complete mini tablet (Roche, Basel, Switzerland)
per 7 ml) and 2 mM NEM, 4 mM PMSF, 5 mM EDTA. The lysates were boiled
for 10 min and 140 mM β-mercaptoethanol was then added. Lysates were used
without centrifugation. 40 μl of each lysate were resolved on SDS-PAGE gel (5%
resolving, 3% stacking), and the rest was stored at −80 °C. Rabbit polyclonal
antibody 297.1 diluted 1:4000 was used to detect total (t) FN, goat polyclonal
antibody 153.1 was used to detect EIIIA (Peters et al., 1996; Peters and Hynes,
1996) and mouse monoclonal antibody SAP.4G5, diluted 1:5000 was used to
detect β-tubulin 1 (T7816, Sigma, St. Louis, MO). The staining was detected
using affinity-purified donkey anti-rabbit, donkey anti-goat and donkey anti-
mouse antibodies conjugated to horseradish peroxidase (Jackson Immunor-
esearch, West Grove, PA) diluted 1:3000 and Western Lightning kit (Perkin
Elmer, Waltham, MA), and quantified using a Storm phosphorimager. Intensity
of FN bands was normalized to that of β-tubulin bands.
Metabolic labeling
Wild-type, heterozygous and nullMEFswere isolated from e14.5 embryos as
described (Nagy et al., 2003). 5×105 cells were plated on 60-mmdishes for 24× h
and labeled using 35S-Methionine/Cysteine (NEN, Waltham, MA) as described
(Senger et al., 1983). Briefly, cells were incubated with 200 μCi in 1 ml of
medium for 2 h, supernatants were collected at 60, 80, 100 and 120 min, and
resolved using 5% SDS-PAGE. To assay incorporation of FN into the cell matrix,
cells were labeled for 2 h, washed, and incubated in label-free medium for 24 h.
Cells were then lysed and FN was immunoprecipitated using 297.1 antibody and
protein G agarose.
Immunohistochemistry and immunofluorescence
Embryos were isolated at e9.5 or e10.5, fixed with 3.75% formalin at 4 °C
overnight and dehydrated through a methanol series (25%, 50%, 75%). They
were then incubated with 6% H2O2 in methanol for 4 h, re-hydrated through the
methanol series and used for whole-mount staining with anti-Pecam 1 antibody
(Pharmingen, Rockville, MD). Embryos were first incubated with blocking
solution (PBS, 0.1% Triton-X-100 and 10% goat serum) at 4 °C overnight, then
with the anti-Pecam 1, diluted 1:100 in the blocking solution, also 4 °C overnight.
Embryos were then washed with PBS containing 0.1% Triton-X-100 overnight
and incubated with affinity-purified donkey anti-rat secondary antibody
conjugated to horseradish peroxidase (Jackson Immunoresearch) at 4 °C
overnight. After washing, the embryos were developed using DAB kit (Vector,
Burlingame, CA). Embryos were then embedded into histogel (VWR, WestChester, PA), fixed with 3.75% formalin at 4 °C overnight and processed for
histology into paraffin blocks. To stain forαSMA, sections were boiled in 10mM
citric acid pH 6.0 for 10 min, incubated with blocking solution containing PBS,
0.05% Tween-20 and 10% donkey serum and then with alkaline-phosphatase-
conjugated antibody to αSMA (A5691, Sigma) in blocking solution. After
overnight incubation at 25 °C, sections were washed and stained using NBT/
BCIP solution (Roche). For detection of EIIIA, EIIIB and tFN, embryos were
fixed in Zn fixative (BD Pharmingen) for 48 h at room temperature, processed for
paraffin embedding and sectioned. Sections were stained using 297.1 antibody to
tFN (1:1000), purified rabbit polyclonal antibody 264.1 diluted to 25 ng/ml to
detect EIIIB exon, and purified goat polyclonal antibody 153.1 diluted to 140 ng/
ml to detect EIIIA exon (Astrof et al., 2004). PBS containing 0.05% Tween-20
and 3% chicken ovalbumin were used as blocking solution and diluent. Staining
was developed using secondary antibodies conjugated to horseradish peroxidase
(described above) diluted 1:200 and DAB kit. Placentae were fixed in 3.75%
formalin at 4 °C overnight, processed for paraffin embedding and sectioned.
Sectionswere either stainedwith hematoxylin and eosin or with rabbit polyclonal
anti-laminin-1 antibody (L9393, Sigma) diluted 1:100 followed by affinity-
purified donkey anti-rabbit antibody conjugated to alkaline phosphatase (Jackson
Immunoresearch) and developed using NBT/BCIP. All sections were counter-
stained with methyl green and observed using an Axiophot microscope.
Immunofluorescence studies to detect tFN, EIIIA and EIIIB splice variants were
performed as described (Peters and Hynes, 1996).Results
Expression of EIIIA and EIIIB splice variants during
embryonic development
The expression patterns of EIIIA and EIIIB splice variants
have been extensively studied previously (ffrench-Constant and
Hynes, 1989; Peters et al., 1996; Peters and Hynes, 1996),
however, we re-examined embryonic expression of these splice
variants in selected embryonic tissues at e10.5, using limiting
amounts of antibodies to detect any possible differential ex-
pression. To our surprise, not all embryonic and extra-embryo-
nic vessels stained well with antibodies to tFN, EIIIA or EIIIB.
In placental labyrinth, embryonic vessels located closer to the
edge but not those located closer to the giant-cell trophoblast
layer expressed FNs; maternal vessels did not detectably
express FNs within the labyrinth (Figs. 1A–D). Interestingly,
within the e10.5 embryo, FN and its splice variants were highly
enriched around dorsal aortae and pharyngeal arch arteries but
were expressed either at very low levels or not at all around
anterior cardinal veins (Figs. 1E–H). Finally, in accord with
previous studies (ffrench-Constant and Hynes, 1989; Peters and
Hynes, 1996), we found expression of EIIIA and EIIIB around
endocardial and cushion cells of the heart (Figs. 1I–K). This
pattern of expression suggested that EIIIA and EIIIB splice
variants might be important for vascularization of placenta, the
development of dorsal aortae and cardiac cushions. To examine
the role of EIIIA and EIIIB splice variants in embryonic
cardiovascular development, we deleted both EIIIA and EIIIB
exons from the FN locus.
Generation of EIIIA and EIIIB double-null animals
EIIIA and EIIIB exons of FN are separated by about 10 kb of
sequence in the mouse genome, thus precluding the possibility
of obtaining EIIIA/EIIIB double-null mice through mating of
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Fig. 1. Expression of EIIIA and EIIIB splice variants of fibronectin during embryonic development. (A–D) Placenta. EIIIA (A), EIIIB (B) and tFN (C) proteins are
expressed around embryonic but not maternal blood vessels. (D) EIIIA /EIIIB-double-null placenta stained for EIIIB. White arrows point to embryonic blood vessels.
Red arrows point to maternal blood vessels. Black arrows point to embryonic vessels lacking FN staining. Red asterisks mark non-specific staining (both EIIIB and
PNGase-independent background staining (Peters et al., 1996)). Scale bars are 30 μm. (E–H) Embryo. tFN as well as EIIIA and EIIIB splice variants are enriched
around arteries but not around veins. Red arrowheads point to arterial vessels and blue arrowheads point to anterior cardinal veins. (E) EIIIA, (F) EIIIB, (G) tFN, (H)
Control—Staining for EIIIB+-FN without PNGase treatment. Scale bars are 130 μm. (I–K) Heart. EIIIA (I), EIIIB (J) and tFN (K) are expressed in cushions (arrows)
and endocardium of the heart. Scale bars are 65 μm.
14 S. Astrof et al. / Developmental Biology 311 (2007) 11–24EIIIA-null and EIIIB-null animals. To obtain the double-null
mice, we isolated EIIIB-null male ES cells of a mixed 129P2/
C57BL6/J background from EIIIB-null zygotes and used the
targeting construct described previously for the generation of
the EIIIA-null allele (Tan et al., 2004) to delete the EIIIA
sequence in these cells. Following sequence-specific recombi-
nation, the floxed EIIIA allele is inserted such that the loxP sites
in the EIIIA and EIIIB loci point toward each other, suggestingFig. 2. Generation of the EIIIA/EIIIB-double-null allele. (A) Generation of the EI
H=HindIII, R=EcoRI. Arrowheads designate PCR primers used for genotyping. M
shows the possible inverted allele. (B) Southern blots. Marker and band sizes are in k
panel c, probe 44sub was used. (a) EcoRI digestion. B8 are EIIIB-null ES cells with th
0.86 kb band corresponds with the EIIIA deletion. (b) BamHI digestion. The 1.9 kb
fragment in panel d corresponds with the EIIIA deletion. EIIIA−/− and EIIIA+/− cells
EIIIA deletion. Arrowheads in panels c–e point to where bands corresponding with th
allele (a) and a Southern blot (b, AvrII, probe 2) for EIIIA allele from a litter of nine e9
double-null embryos. (D) (a) Genomic PCR to detect EIIIA+, EIIIB+, EIIIA−, and EIII
(c) Western blot to detect tFN, EIIIA and β-tubulin from a litter of six e9.5 embryos d
embryos. (E) (a) Time-course of FN secretion into the medium and (b) FN incorpora
and double-het MEFs.that treatment with Cre recombinase might result in the
inversion of the region. Fig. 2A shows the wild-type and the
EIIIA-null genomic loci, containing loxP sites in place of
EIIIA and EIIIB exons, in correct and in inverted orientations.
We performed five Southern blot experiments using four
different restriction enzymes and two different probes to show
that the EIIIA locus is targeted correctly (Figs. 2B (a–e)) and that
the region between the EIIIA and EIIIB exons is positioned inIIA−EIIIB− allele. Top panel represents wild-type locus. A=AvrII, B=BamHI,
iddle panel represents the correctly targeted EIIIA−EIIIB− allele. Bottom panel
ilobases (kb). Blots in all panels except panel c were performed with probe 2; in
e wild-type EIIIA+ allele, lane numbers are names of targeted ES cell clones. The
band corresponds with the EIIIA deletion. (c and d) AvrII digests. The 2.9-kb
were used as controls. (e) HindIII digest. The 3 kb band corresponds with the
e possible inverted allele would have been located. (C) Genomic PCR for EIIIB
.5 embryos derived from EIIIA−EIIIB−/EIIIA+EIIIB+ intercross. Asterisks denote
B− alleles, (b) RT-PCR to detect EIIIA+, EIIIB+, EIIIA−, and EIIIB−mRNA, and
erived from EIIIA−EIIIB−/EIIIA+EIIIB+ intercross. Asterisks denote double-null
tion into the extracellular matrix of metabolically labeled wild-type, double-null
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Table 1
Genotype Age
Wild type Het Null
88 145 12 Adult (129S4/C57BL6/J mixed)
18 39 0 Adult (129S4) a
10 19 4 Adult (C57BL6/J)a
19 (1) 44 (3) 26 (12) e9.5(129S4/C57BL6/J mixed)
15 (1) 43 (4) 16 (13) e10.5(129S4/C57BL6/J mixed)
Numbers in parenthesis are the numbers of abnormal embryos.
a These distributions are statistically different: p=0.002, χ2 test.
16 S. Astrof et al. / Developmental Biology 311 (2007) 11–24the correct orientation with respect to FN (Figs. 2B (c–e)). The
targeted EIIIA−EIIIB−/EIIIA+EIIIB− ES cells were then injected
into FVB/NJ wild-type blastocysts and the resulting chimeric
mice were mated to wild-type C57BL6/J females. We verified the
transmission of the EIIIA−EIIIB− allele using Southern blotting
(data not shown) and intercrossed EIIIA−EIIIB−/EIIIA−EIIIB+
mice to obtain e9.5 embryos, which were then used to verify the
absence of EIIIA and EIIIB sequences in the FN DNA, mRNA
and protein of the double-null embryos (Figs. 2C, D and 3). Our
data indicate that, indeed, the double-null embryos lacked both
EIIIA and EIIIB exons (Figs. 2C and 3) and that the deletion of
both of these exons did not compromise the expression of FN
mRNA (Fig. 2D) and protein (Figs. 2C and 3), nor the deposition
of FN into the matrix (Fig. 2E, Fig. S1 and Table S1).
Interbreeding of EIIIA−EIIIB−/EIIIA+EIIIB+ mice (mixed
C57BL6/J and 129P2 background) produced only 18% of the
expected number of double-null adults (Table 1), suggesting that
the absence of both EIIIA and EIIIB is embryonic lethal with
about 80% penetrance. Indeed, 50% of e9.5 and 80% of e10.5
double-null embryos showed severe cardiovascular defects
(Fig. 4), and were absorbed by e11.0 (Table 1 and data not
shown). Interestingly, the ability to survive in the absence of
EIIIA and EIIIB had a statistically significant genetic back-
ground component (Table 1). Intercrosses of double-hetero-
zygous mice, backcrossed six times to 129S4 strain, did not
produce any live progeny (fifty seven live mice were examined,
representing nine litters), while about 50% of the expected
number of the double-null mice were born from EIIIA−EIIIB−/
EIIIA+EIIIB+ mice backcrossed six times to C57BL6/J strain
(thirty three live mice were examined, representing eight litters).
The partial viability of EIIIA/EIIIB-double null mice bred to
C57BL6/J as opposed to 129S4 background is consistent with
the observation that the phenotype of FN-null mice is milder on
C57BL6/J than on 129S4 background (George et al., 1997;
Astrof et al., in press).A B
C D
EIIIA
EIIIA
wt wt
null null
Fig. 3. EIIIA/EIIIB-double-null embryos express only EIIIA− and EIIIB− FN. (A)
EIIIB+ −FN in wild-type littermate control embryos. The vessel stained is dorsal a
EIIIA (C) and EIIIB (D) expression, whereas FN (E, green) is expressed. DAPI wPhenotypes of EIIIA and EIIIB double-null embryos
There was heterogeneity of phenotype among the double-null
embryos in the mixed background crosses. About half of the
double-null embryos ofmixed genetic background showed severe
cardiovascular defects by e9.5. These defects included hemor-
rhage within the embryo (83% of all defective embryos) and
anemia due to leakage of blood (Figs. 4A, B, G), shortened
posterior, kinked neural tube (5% of all defective embryos) (Fig.
4A) and blistered appearance of the yolk sac (30% of all defective
embryos) resulting from separation of endodermal and mesoder-
mal layers (Figs. 4B, J, K). These defects are reminiscent of, but
milder than, the defects in FN-null or in FN-receptor, in-
tegrin α5-null embryos. By e10.5 about 80% of the double-null
embryos showed vascular defects (Figs. 4D, E). These defects
included embryonic hemorrhage (100%), dilation of pericardial
cavity (50%), and thinned outflow tract (30%) (Fig. 4D). A small
number of double-null embryos (about 7%) appeared morpholo-
gically normal (compare Figs. 4E and F) but exhibited focal
hemorrhage in the head (Figs. 4E, I); the yolk sac vasculature and
the heart developed normally in these embryos (data not shown).
Embryonic vascular development in the double-null embryos
was analyzed by detecting vessels with antibody specific for the
endothelial marker Pecam-1 (Fig. 5; summarized in Table 2). AtE
EIIIB
EIIIB tFN
null
Sagittal sections through e9.5 embryos show expression of EIIIA+ and (B)
orta. (C–E) Yolk sacs of e 9.5 EIIIA/EIIIB-double-null embryos show lack of
as used to stain nuclei. Scale bars are 30 μm.
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Fig. 4. Phenotypes of EIIIA/EIIIB-double-null embryos. (A–C) Representative double-null (A, B) and wild-type (C) embryos at day e9.5 of development are shown.
Note hemorrhage, truncated posterior and a kinked neural tube in panel A, and avascular and blistered yolk sac in panel B. (D–F) Representative double-null (D, E) and
wild-type (F) embryos at e10.5 are shown. Note shortened and hemorrhagic posterior and a thinned outflow tract (arrows) in panel D and a localized head hemorrhage
(arrow) in panel E. Scale bars are 1 mm. (G–I) Sagittal sections through embryonic hearts at e9.5 (G, H) and a transverse section through an e10.5 embryonic head (I).
Arrows in panel G point to blood in pericardial cavity as well as in the space between endocardial and muscle layers; arrows in panel I points to hemorrhage in the head.
Scale bars are 30 μm. (J, K) Sections through wild-type and double-null yolk sacs. Arrowheads mark mesodermal (m) and endodermal (e) layers. Note the separation of
these layers in panel K. Bracket marks placenta in panel J.
17S. Astrof et al. / Developmental Biology 311 (2007) 11–24e9.5, double-heterozygous embryos (Fig. 5A) and some mor-
phologically normal double-null embryos (Fig. 5B) had correctly
patterned vasculature with large vessels and a finely patterned
vascular plexus in the head and body. In contrast, in severely
affected double-null embryos (Fig. 5C) and even in some
morphologically normal e9.5 double-nulls (Fig. 5D), there were
few and dysmorphic large vessels in the head, and small vessels in
the head and body appeared syncytial with endothelial cells
forming sheets instead of tubes (Figs. 5C, D, I, J). Interestingly,
we observed two kinds of vascular defects in morphologically
normal double-nulls. Some of them presented with a syncytial
head vasculature (Fig. 5D), these embryos would presumably be
dying by e10.5; others developed a normal vascular plexus of
small vessels but abnormal patterning of the large head veins,
where vessels appeared blunt-ended and discontinuous (Fig. 5E).
Vascular defects in the double-null embryos at e10.5 could
also be divided into two groups—the most severely affected
embryos had syncytial vasculature with endothelial cellsforming sheets instead of tubes (Fig. 5G) and less severely
affected, morphologically normal double-null embryos, with
abnormally patterned, blunt-ended and constricted head veins
(Fig. 5H). It is plausible that one of these constricted vessels
could rupture leading to focal hemorrhage in the head.
Extraembryonic vascular defects
Most but not all morphologically abnormal double-null
embryos exhibited defects in the development of yolk sac and
placental vasculature. Embryos with blistered yolk sacs had
unremodeled and dilated yolk sac vessels and a general lack or
degeneration of large vessels (Figs. 6A–D and data not shown).
About 90% of embryos showing severe intra-embryonic vascular
defects also had defective yolk sac vasculature, suggesting that
EIIIA and EIIIB splice variants function in embryos and yolk sacs
to remodel the initial uniform vascular plexus into a more mature
pattern with large and small vessels.
het null null null null
het nullnull
het null
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Fig. 5. Head vasculature in double-null embryos at e9.5 and e10.5. (A–E) Pecam-1 staining of e9.5 heads. Note a regular pattern of small and large blood vessels in a
heterozygous (A) and in a grossly normal double-null embryo (B), compared with a syncytial appearance of small head vessels in a morphologically defective (C) and
a grossly normal (D) double-null embryo. Note blunt-ended and interrupted vessels in another grossly normal double-null embryo (E). (F–H) Pecam-1 staining of
e10.5 heads. Note a regular pattern of small and large vessels in a heterozygous (F) embryo as opposed to syncytial appearance of small vessels and the scarcity of large
vessels in a morphologically abnormal double-null embryo (G), as well as short, blunt-ended and interrupted head vessels in a grossly normal double-null (H). Brackets
highlight syncytial endothelial sheets in panels C, D and G and arrows point to blunt-ended vessels in panels E and H. Scale bars are 1 mm in all except panel H, where
scale bar is 240 μm. (I–J) Transverse sections through heads of a heterozygous (I) and a double-null (J) embryo at e10.5 show the presence of small vessels in the head
and vessel invasion into the neural fold in the heterozygote (I). In the double-null (J) the vessels appear dilated, resulting from two sheets of endothelial cells touching
each other in some places. Also note the lack of vascular invasion into the neural fold in the double-null (J). Scale bars are 65 μm.
18 S. Astrof et al. / Developmental Biology 311 (2007) 11–24Placental vascularization was also defective in some (∼50%)
of the abnormal double-null embryos (Figs. 6E–H). Starting at
e8.5, embryonic vessels invade placenta and by e10.5 form
elaborate finger-like projections in the placental labyrinth (Figs.
6E, G). However, in about 50% of the double-null embryos,
placental vascularization following the invasion with embryonic
vessels was much less extensive (Figs. 6F, H). While vessels did
enter the labyrinth layer initially in these embryos, they failed to
form extensive projections and branches, suggesting that EIIIA
and EIIIB splice variants are important for vascularization of thisTable 2
Appearance of head vessels a
e9.5
Normal Syncytial b
Grossly abnormal nulls 0 2
Grossly normal nulls 2 3
Grossly normal hets 10 1
a Detected by anti-Pecam-1 antibody staining.
b Syncytial refers to the appearance of small vascular plexus in the head.
c Blunt refers to the appearance of large head veins.
d In addition to these five, two other embryos had unremodeled head vasculatureinitially avascular placental layer. Since only about half of the
e9.5 and e10.5 abnormal embryos had defects in placental
vascularization, aberrant placental development was not the
cause or the consequence of embryonic vascular defects,
suggesting independent roles for EIIIA and EIIIB in both
embryonic and placental vascular development. Similarly,
defective yolk sac vasculature was not a cause or a consequence
of defective placental angiogenesis, suggesting independent
roles for EIIIA and EIIIB splice variants in both yolk sac and
placental vascularization. Thus, these different developmentale10.5
Blunt c Normal Syncytial Blunt
0 0 5 d 1
2 2 0 2
0 5 0 0
with dilated small vessels and very few large vessels in the head.
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Fig. 6. Extraembryonic vascular defects in EIIIA/EIIIB-double-null embryos. (A–D) Yolk sacs. (A, B) EIIIA/EIIIB-double-null yolk sacs showing normal (A) and
defective (B) vasculature. Yolk sac in panel A has large (arrows) and small blood vessels while the one in panel B has only one large vessel (arrow) and abnormally
patterned small vessels. (C, D) A heterozygous and a double-null yolk sac stained with antibody to Pecam-1. White arrows point to vitelline vessels and black arrows
point to large yolk sac blood vessels. Notice the size and the regular pattern of yolk sac vessels in panel C, and syncytial appearance of vasculature and absence of large
blood vessels in panel D. Scale bars are 1 mm. (E–H) Placental labyrinths (brackets) in heterozygous (E and G) and double-null (F and H) embryos. Note extensive
embryonic vasculature permeating the labyrinthine layer in panel E and the scarcity of embryonic blood vessels in panel F. Filled arrows point to embryonic and open
arrowheads to maternal vessels. (G, H) Vascular pattern in the labyrinth layer is revealed with an antibody to laminin1. Note abundant finger-like vascular projections
in heterozygous (G) but not double-null (H) placenta. Scale bars are 65 μm.
19S. Astrof et al. / Developmental Biology 311 (2007) 11–24defects in different vascular beds can be uncoupled and appear to
be independent consequences of the lack of EIIIA and EIIIB
splice variants.
Heart defects in the EIIIA/EIIIB double-null embryos
Most of the affected double-null embryos had gross morpho-
logical heart defects such as edema and thinned or dilated out-
flow tracts (Figs. 4D, 7A). Some embryos (three out of six
morphologically abnormal e10.5 double-nulls analyzed) had
defects in cardiac cushion formation (Figs. 7A, Ba and Fig. S2).
One of the embryos contained multilayered endothelium in the
outflow tract with no evidence of cushion cell differentiation(Fig. 7Ba), another had multiple layers of endothelium in the
atrio-ventricular cushions (not shown), while in the third double-
null embryo, cushion cells did develop, but were cuboidal in
shape and did not express phosphorylated SMAD2 (Fig. S2),
suggesting a role for EIIIA and EIIIB splice variants in
transformation of endocardial cells into cushion cells.
Vascular smooth muscle cell development in the double-null
embryos
Earlier studies had suggested a role for EIIIA in induction of
αSMA (Serini et al., 1998). However, our previous studies
indicated that, individually, the absence of either EIIIA or EIIIB
BA
a) b)
d)c)
null
wt
null null
wt wt
Fig. 7. Defects in heart cushion formation and in association of αSMA cells with dorsal aortae of e10.5 embryos. (A) Whole mount Pecam-1 stain revealing blood
vessel pattern. Arrowheads point to outflow tracts in double-null and wild-type embryos. Notice a thin outflow tract as well as abundant Pecam-1 reactivity within the
outflow tract of the double-null embryo as compared with the wild-type embryo. (B) Transverse sections through embryonic hearts. Notice multilayering of endothelial
cells in (a) compared with (c). Scale bars are 130 μm. (b and d) αSMA cells are closely associated with dorsal aorta in the wild-type embryos while in the double-null
embryo, the αSMA cells are rounded and not well spread around the vessel. Scale bars are 15 μm.
20 S. Astrof et al. / Developmental Biology 311 (2007) 11–24did not affect expression ofαSMA in tumor stroma (Astrof et al.,
2004). Specific expression of FN and its splice variants around
dorsal aortae in embryos suggested that these splice variants
might play a role in the development of aortic vessels during
embryogenesis. The most notable difference between dorsal
aortae and anterior cardinal veins in e9.5 and e10.5 embryos is
the presence of vascular smooth muscle cells expressing αSMA
specifically around dorsal aortae but not around anterior cardinal
veins (Fig. 7; (Li et al., 2003). To examine smooth muscle cell
association with the aortae, e9.5 and e10.5 embryos were stained
using both anti-Pecam 1 and anti-αSMA antibodies, and the
number, association, and morphology of αSMA-positive cells
were assessed. Enumeration of αSMA-positive cells around
dorsal aortae at e9.5 indicated that there was a statistically
significant difference in the number of αSMA-positive cells
closely associated with dorsal aortae in EIIIA/EIIIB-double null
embryos compared with their heterozygous littermates (Figs.
8A, B). Both morphologically normal and abnormal double-null
embryos showed a decrease in the number of vascular smooth
muscle cells (Fig. 8A). By e10.5 most of the dorsal aortae in
morphologically abnormal double-null embryos were sur-
rounded by αSMA-positive cells, suggesting that there is only
a delay in recruitment or differentiation of these cells in the
double-nulls. Interestingly, three of five double-null embryos at
e10.5 contained αSMA-positive cells beyond the immediate
vicinity of the vessels (Figs. 8C–E), suggesting that there is a
defect in migration of αSMA-positive cells to dorsal aortae in
the double-null embryos. These e10.5 double-null embryos also
had defective association of αSMA-positive cells with the
endothelium of dorsal aorta (Figs. 7B, a–d). Instead of being
closely opposed to the endothelial lining of the vessel, the
αSMA-positive cells were rounded, suggesting a defect in
vascular smooth muscle cell spreading along the vessel wall.Taken together, our experiments suggest that EIIIA and EIIIB
splice variants function in recruitment, differentiation and
associations of aortic αSMA cells to vessels in vivo.
Discussion
The alternative splicing of EIIIA and EIIIB was discovered
about 20 years ago (Kornblihtt et al., 1984b; Schwarzbauer et al.,
1987) and a myriad of studies that followed attempted to address
the functions of EIIIA and EIIIB splice variants in cell culture
and in vivo. However, this turned out to be a difficult problem
largely because FN is a complex multidomain protein. It is
difficult to produce full-length FN in a recombinant form and it is
hard to deplete cells or media completely of FN, hampering
reconstitution studies. Unexpectedly, mice carrying individual
deletions of EIIIB or EIIIA exons were viable and fertile
(Fukuda et al., 2002;Muro et al., 2003; Tan et al., 2004,), and did
not provide insight into why the sequences and patterns of
expression of EIIIA and EIIIB are so highly evolutionarily
conserved. It is possible that EIIIA and EIIIB are overlapping in
function. However, the fact that their sequences are only about
30% identical to each other in a given species argues to some
extent against this model. Alternatively, while EIIIA and EIIIB
may be important in the same biological process (e.g. blood
vessel development), their functions could differ, but the
presence of one splice variant is sufficient to support life in the
artificial environment of a mouse cage. Lastly, the phenotypes of
gene deletions often vary depending on genetic background, and
it is possible that unknown genetic factors allowed the survival
and function of EIIIA-null or EIIIB-null mice, both of which
have been backcrossed to C57BL6/J genetic background.
Analysis of genomes from different phyla have suggested that
FN is unique to vertebrates (Whittaker et al., 2006). The
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Fig. 8. Quantification of αSMA cells around dorsal aortae at e9.5 and e10.5. αSMA cells around each of the two dorsal aortae were enumerated. (A) 97 serial sections
from seven heterozygous embryos representing four different litters and 126 serial sections from eleven double-null embryos representing five different litters were
examined. The numbers ofαSMAcells per section around the two dorsal aortae are plotted. Individual embryos are presented along the abscissa. Embryo number 10was
anemic. (B) Summary of the results in panel A presented as a box plot (the box contains the middle 50% of the data, the horizontal line within the box is the median,
points outside of the whiskers (10–90% of data) are outliers). (C) Delay in recruitment of αSMA cells to dorsal aortae in embryos at e10.5 dpc. Three out of five closely
examined, morphologically defective double-null embryos representing three different litters had a defect in recruitment of αSMA+ cells to dorsal aortae. (D, E)
Transverse sections through a heterozygous and a double-null embryo stained with antibodies to Pecam-1 and αSMA show excess of αSMA+ cells outside of the
immediate proximity of the dorsal aortae. Blue and red arrowheads point to veins and arteries respectively, green arrowhead points to αSMA+ cells. Scale bars are
130 μm.
21S. Astrof et al. / Developmental Biology 311 (2007) 11–24expression pattern of FN together with the severe vascular
abnormalities in FN-null embryos suggested that FN functions
in blood vessel development and may have evolved for that
purpose. The alternatively spliced forms of FN containing EIIIA
and EIIIB are also expressed around developing vasculature
suggesting that they too may function in some aspect of vessel
development. Indeed, we found that the absence of both EIIIA
and EIIIB exons from FN message resulted in embryonic lethal
cardiovascular defects.
The absence of EIIIA and EIIIB gives rise to pleiotropic
vascular defects ranging from severe to mild malformations and
some progeny survive. We noticed that about 20% of double-
null mice were viable and fertile on a mixed 129P2/C57BL6/J
background, while on a relatively pure C57BL6/J (six gene-
rations of backcrossing) about 50% survived to adulthood,
appeared normal and were fertile (unpublished data). In
contrast, no adult double-null mice have been observed in
129S4 strain (backcrossed for six generations). Thus the
pleiotropic nature of the cardiovascular defects in the EIIIA/
EIIIB double-null mice could in part be explained by segregating
genetic factors in the mixed 129P2/C57BL6/J population. We
have previously reported that the embryonic-lethal phenotype of
FN-null embryos is more severe on a 129S4 than a C57BL/6
background (George et al., 1997) and we have mapped a strain-specific genetic modifier affecting the difference (Astrof et al., in
press). It is possible that the same modifier is affecting the
phenotype of the EIIIB/EIIIA double-null embryos and this will
need to be investigated.
Most of the defective embryos showed various forms of heart
defects. The most severely affected embryos displayed heart
defects by e9.5. These defects included inflated pericardial
cavity, pericardial edema, degenerating linear heart tube, or
dilated aortic sac (data not shown). The embryos surviving to
e10.5 also had similar defects. Since EIIIA and EIIIB splice
variants are expressed in endocardial cells and in cardiac cushion
cells, we examined whether there is a defect in the development
of cardiac cushions. Three out of the six closely examined e10.5
embryos showed cushion defects, suggesting a role for EIIIA
and EIIIB in this epithelial to mesenchymal transition in the
heart. It is possible that examination of cardiac malformations in
a pure background (129S4 or C57BL6/J) may decrease varia-
bility in the phenotype making it more amenable to study.
Not all vascular beds were defective in EIIIA/EIIIB double
null mice; for example, small vessels in the yolk sac, head and
trunk were syncytial in the severely affected embryos, but
endothelial tubes of dorsal aortae and intersomitic vessels
formed apparently normally. This could be due to different
requirements for EIIIA and EIIIB in blood vessel development
22 S. Astrof et al. / Developmental Biology 311 (2007) 11–24in different embryonic compartments. In addition, EIIIA and
EIIIB seem to play distinct roles in vascularization of different
tissues. For example, in severely affected embryos, the absence
of EIIIA and EIIIB in yolk sacs and in the head resulted in
defective vascular remodeling while in the placenta, the absence
of EIIIA and EIIIB led to defects in angiogenesis (sprouting of
the new vessels from the pre-existing ones).
Embryonic vessels in the placenta are derived from allantoic
vessels, which invade the placental labyrinth following the
attachment of allantois to placenta by e8.5 of development. We
did not see any differences in the invasion of the labyrinth layer
by embryonic vessels, neither at e8.5 nor at e9.5 (data not
shown), however we observed many fewer vessel sprouts in the
labyrinth of some e10.5 embryos suggesting that, in the placenta,
EIIIA and EIIIB function in vessel sprouting. It is unclear why
vascularization of only some placentae was affected. This could
be due to genetic differences or stochastic events. In either case,
embryonic vascular defects did not arise as a consequence of
defective placental vascularization since only about half of the
defective embryos exhibited defective placentae. In support of
this conclusion, Gcm-1 null embryos, in which placental
labyrinth does not have any embryonic blood vessels, do not
develop intra-embryonic vascular defects (Anson-Cartwright
et al., 2000).
FN-null mutations in mice and zebrafish as well as FN-
blocking experiments in frogs showed that the absence of FN
affects organ assembly but not specification of precursor cells
(George et al., 1993; Marsden and DeSimone, 2001; Marsden
and DeSimone, 2003; Trinh and Stainier, 2004). For example,
somite, notochord and heart precursors are specified but none of
these assemble into proper somites, notochord or heart
structures. While the molecular mechanisms of these defects
are not completely clear, in both zebrafish and frogs, the absence
of FN alters cell polarity leading to defects in polarized cell
movements during migration of heart primordia toward the
midline in fish or during convergent extension in frogs. Vascular
defects in FN-null and EIIIA/EIIIB-null embryos could also be a
consequence of defects in endothelial cell polarity resulting in
aberrant endothelial tube formation. Small vessels do not form
properly in the heads of severely affected EIIIA/EIIIB double-
null embryos; instead of distinct vessel tubes, we observed two
sheets of endothelial cells that occasionally touch each other
forming dilated vessel lumens (very similar to the ones seen in
severely affected yolk sacs). Studies of tube formation during the
past 10 years have shown that lumen formation in epithelial or
endothelial systems (and others) requires the establishment of
apical (luminal) and basolateral (abluminal) polarity through the
biogenesis of apical cell surfaces and exocytosis of vacuoles at
the apical membrane (Lubarsky and Krasnow, 2003). It is
tempting to speculate that formation of endothelial sheets instead
of tubes may be due to a defect in endothelial apical–basolateral
polarity in the absence of both EIIIA and EIIIB.
While aortae do form in EIIIA/EIIIB double-null embryos,
we noticed a statistically significant difference in the numbers of
αSMA+ cells immediately surrounding each dorsal aorta. At
e9.5, there were three-fold fewer αSMA+ cells around aortae in
the double-null embryos compared with their heterozygouslittermates. With the exception of a few embryos that had
very few aortic αSMA+ cells, by e10.5 most of the double-null
embryos contained αSMA+ cells around their aortae suggesting
that there is a delay in recruitment or differentiation of αSMA+
cells in the double-null embryos. Whereas present experiments
cannot precisely distinguish between these possibilities, we
think that there is a delay in recruitment of these cells since in
e10.5 embryos some αSMA+ cells surround the dorsal aortae
but a number of others are located a few cell diameters away
from the actual vessel. Interestingly, αSMA+ cells around dorsal
aortae are derived from paraxial mesodermal precursors that
also give rise to somites. These precursors express Pax3 and are
seen migrating toward the dorsal aortae from their paraxial
locations (Esner et al., 2006). It would be interesting to examine
migration of these cells in EIIIA/EIIIB double-null embryos.
Whatever the cellular mechanisms contributing to the vas-
cular defects we describe, it will also be necessary to define the
underlying molecular functions of the EIIIA and EIIIB
segments. As discussed earlier, this has proven to be difficult
in the past but future studies will be given impetus by the
evidence for important in vivo functions of these segments. It has
been reported that the EIIIA segment can bind to integrins α4β1
andα9β1 (Liao et al., 2002) and to the Toll-4 receptor (Okamura
et al., 2001), although the functional implications of these
bindings have not been elucidated. Fibronectin has also been
reported to bind several growth factors involved in angiogenesis;
VEGF (Wijelath et al., 2002) and HGF (Rahman et al., 2005).
The potential involvement of these various properties in vascular
development will need to be investigated.
The existence of the alternatively spliced EIIIA and EIIIB
segments of FN has been known for 20 years and the high level
of conservation of their sequences and of their tightly regulated
patterns of splicing has indicated that they provide some evolu-
tionary conserved function(s). However, in vitro analyses over
the past two decades have failed to reveal clear roles for these
segments. Our studies demonstrate for the first time that EIIIA
and EIIIB-containing splice variants of FN are crucially in-
volved in cardiovascular development. The molecular mech-
anisms of their functions, as well as elucidation of the individual
roles of EIIIA and EIIIB, will await further detailed in vitro and
in vivo studies. The mice we report here and cells derived from
themwill provide valuable reagents for these investigations. The
availability of mouse strains showing both embryonic defects
and postnatal viability (depending on genetic background) will
allow analyses of a variety of developmental, physiological and
pathological situations.
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